FR6928M - - Google Patents

Info

Publication number
FR6928M
FR6928M FR129489A FR129489A FR6928M FR 6928 M FR6928 M FR 6928M FR 129489 A FR129489 A FR 129489A FR 129489 A FR129489 A FR 129489A FR 6928 M FR6928 M FR 6928M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR129489A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to FR129489A priority Critical patent/FR6928M/fr
Priority to BE710483D priority patent/BE710483A/xx
Priority to DE19681668933 priority patent/DE1668933A1/de
Priority to GB02757/68A priority patent/GB1175808A/en
Application granted granted Critical
Publication of FR6928M publication Critical patent/FR6928M/fr
Priority to DE19702016934 priority patent/DE2016934A1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR129489A 1967-11-24 1967-11-24 Expired FR6928M (el)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR129489A FR6928M (el) 1967-11-24 1967-11-24
BE710483D BE710483A (el) 1967-11-24 1968-02-07
DE19681668933 DE1668933A1 (de) 1967-11-24 1968-02-10 In 3-Stellung substituierte 4-Hydroxycumarine
GB02757/68A GB1175808A (en) 1967-11-24 1968-03-15 Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
DE19702016934 DE2016934A1 (en) 1967-11-24 1970-04-09 4-hydroxycoumarine anticoagulants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR129489A FR6928M (el) 1967-11-24 1967-11-24

Publications (1)

Publication Number Publication Date
FR6928M true FR6928M (el) 1969-05-05

Family

ID=8642199

Family Applications (1)

Application Number Title Priority Date Filing Date
FR129489A Expired FR6928M (el) 1967-11-24 1967-11-24

Country Status (3)

Country Link
BE (1) BE710483A (el)
FR (1) FR6928M (el)
GB (1) GB1175808A (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048090B1 (es) * 1992-01-31 1994-10-01 Rovi Lab Farmaceut Sa Procedimiento para la obtencion de nuevos antitromboticos derivados de la cumarina.
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
BE710483A (el) 1968-06-17
GB1175808A (en) 1969-12-23

Similar Documents

Publication Publication Date Title
AU425114B2 (el)
AU416737B2 (el)
AU2277767A (el)
AU342066A (el)
AU610966A (el)
AU2977667A (el)
AU2116667A (el)
AU2256867A (el)
AU3189468A (el)
AU2454867A (el)
AU3151267A (el)
AU2528767A (el)
BE692922A (el)
BE609934A (el)
AU25066A (el)
AU2406369A (el)
AU1868267A (el)
AU34866A (el)
AU408412B2 (el)
AU1763766A (el)
BE709036A (el)
BE509738A (el)
BE709497A (el)
BE709388A (el)
AU97666A (el)

Legal Events

Date Code Title Description
ST Notification of lapse